University of California, Irvine
This is a phase I/II protocol investigating whether Nelfinavir can improve anemia and lower serum fibrosis biomarkers in Myelofibrosis patients.
Inclusion Criteria: * ≥18 years of age * Have a diagnosis of myelofibrosis (MF) according to the 2016 WHO criteria * Has a hemoglobin ≤ 10gm/dL at screening * Serum ferritin ≥ 100 * May continue on current MPN treatment, including aspirin, hydroxyurea, interferon-alpha, ruxolitinib, fedratinib, or anagrelide. * Peripheral blast count \<10% during Screening. * Free of other known active or metastatic malignancies other than localized skin cancer. * Amenable to blood draws and symptom assessments. * Agree to the use of contraceptives. Female subjects of childbearing potential and their male par…
Taken twice daily
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.